Compound formula of danshen (salvia miltiorrhiza) and gegen (pueraria lobata) as adjunctive secondary preventive therapy in coronary patients.

• Other Authors: Tam, Wing Yin.
• Format: Others
• Language: English; Chinese
• Published: 2004
• Subjects: Salvia > Therapeutic use; Kudzu > Therapeutic use; Coronary heart disease > Prevention; Coronary heart disease > Treatment; Salvia miltiorrhiza > therapeutic use; Pueraria > therapeutic use; Coronary Disease > prevention & control; Coronary Disease > therapy
• Online Access: http://library.cuhk.edu.hk/record=b5891956; http://repository.lib.cuhk.edu.hk/en/item/cuhk-324611

Tam Wing Yin. === Thesis (M.Phil.)--Chinese University of Hong Kong, 2004. === Includes bibliographical references (leaves 82-100). === Abstracts in English and Chinese. === English abstrac --- p.I === 中文摘要 --- p.VI === Glossary --- p.X === Chapter Chapter 1. --- Background: === Chapter 1.1. --- Coronary heart disease in Hong Kong --- p.1 === Chapter 1.2. --- Coronary heart disease and atherosclerosis --- p.2 === Chapter 1.3. --- Pathogenesis of atherosclerosis --- p.2 === Chapter 1.4. --- Risk factors for atherosclerosis --- p.5 === Chapter 1.5. --- Homocysteine --- p.6 === Chapter 1.6. --- Folate --- p.10 === Chapter 1.7. --- Vitamin B12 --- p.13 === Chapter 1.8. --- Adhesion Molecules --- p.14 === Chapter 1.9. --- Phytoestrogen --- p.17 === Chapter 1.10. --- Secondary prevention of coronary artery disease --- p.20 === Chapter Chapter 2. --- "Heart disease, Danshen and Gegen in Chinese medicine" === Chapter 2.1. --- The record of Cardiac symptoms in Chinese Medicine --- p.24 === Chapter 2.2. --- Danshen (Salvia Miltriorrhiza) --- p.25 === Chapter 2.3. --- Gegen (Radix Pueraria) --- p.28 === Chapter Chapter 3. --- Surrogate atherosclerotic markers === Chapter 3.1. --- Flow-mediated dilatation of brachial artery (FMD) --- p.31 === Chapter 3.2. --- Carotid intima media thickness (IMT) --- p.32 === Chapter Chapter 4. --- Method === Chapter 4.1. --- Rational of the study --- p.33 === Chapter 4.2. --- Clinical protocol --- p.35 === Chapter 4.3. --- Measurement of plasma homocysteine --- p.38 === Chapter 4.4. --- Measurement of folate and vitamin B12 --- p.40 === Chapter 4.5. --- Measurement of soluble cellular adhesion molecules (CAMs) --- p.41 === Chapter 4.6. --- Measurement of plasma enterolactone --- p.43 === Chapter 4.7. --- Measurement of plasma hs-C-reactive protein --- p.44 === Chapter 4.8. --- Other laboratory tests --- p.45 === Chapter 4.9. --- High resolution ultrasound imaging --- p.46 === Chapter 4.10. --- Statistical analysis --- p.49 === Chapter 4.11. --- My contribution to this joint project --- p.49 === Chapter Chapter 5. --- Results === Chapter 5.1. --- Recruitment and outcomes of subjects --- p.51 === Chapter 5.2. --- Baseline characteristics --- p.53 === Chapter 5.3. --- Medical history and treatment received in the study subjects --- p.54 === Chapter 5.4. --- Safety profiles --- p.55 === Chapter 5.5. --- Severe adverse events --- p.56 === Chapter 5.6. --- Lipid profiles --- p.57 === Chapter 5.7. --- Secondary endpoints --- p.58 === Chapter 5.8. --- Primary endopoints --- p.59 === Chapter 5.9. --- The effect of statin usage on the primary endpoints === Chapter 5.10. --- The major determinant of the change in FMD by multivariate logistic regression === Chapter 5.11. --- Progress of lipid profiles and primary endpoints in the open label phase === Chapter Chapter 6. --- Discussion === Chapter 6.1. --- Brachial FMD --- p.66 === Chapter 6.2. --- Carotid IMT --- p.69 === Chapter 6.3. --- Brachial GTN --- p.70 === Chapter 6.4. --- Lipid-lowering effect --- p.72 === Chapter 6.5. --- Phytoestrogen --- p.72 === Chapter 6.6. --- Folate --- p.73 === Chapter 6.7. --- Vitamin B12 and glucose --- p.76 === Chapter 6.8. --- Summary of possible anti-atherogenic mechanism of D&G --- p.76 === Chapter 6.9. --- Placebo effect --- p.77 === Chapter 6.10. --- Safety profile --- p.77 === Chapter 6.11. --- Limitation of the study and suggestion of solution --- p.77 === Chapter 6.12. --- Suggestions and ummary of the future work --- p.79 === Chapter Chapter 7. --- Conclusions --- p.81 === References --- p.82